Much is yet to be learned regarding which clinical agents will pair most effectively with Ref-1/APE1 redox or repair inhibitors; however, studies are ongoing to determine whether this approach will yield drug combinations that are synthetically lethal to cancer cells. This evidence concerns the gene APEX1 and cancer.